Tag
PDS0101 combined with pembrolizumab demonstrated encouraging efficacy and safety in immune checkpoint inhibitor-naive HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma, supporting further first-line evaluation.
Tissue-informed circulating tumor DNA assays demonstrate high detection rates and exceptional sensitivity and specificity in monitoring HPV-positive and HPV-negative head and neck squamous cell carcinoma, supporting their clinical utility i
Neoadjuvant chemoimmunotherapy significantly improves pathologic response rates in resectable head and neck squamous cell carcinoma compared to immunotherapy alone, potentially transforming preoperative treatment strategies.
This study identifies specific cancer-testis antigens (CTAs) as promising targets for personalized immunotherapy in head and neck squamous cell carcinoma (HNSCC), validated across multiomic datasets to enhance therapeutic precision.
A phase 2 trial reveals that senolytic agents combined with anti-PD-1 immunotherapy enhance pathological response rates in head and neck squamous cell carcinoma by mitigating immunosenescence, with promising safety profiles.
